To disclose risk factors of incident aortic stenosis (AS) and progression of established AS. A prospective cohort study. The Tromsø Study, a population based health survey. Over a 14 years span we performed three repeated echocardiographic examinations (1994, 2001 and 2008) of a random sample of initially 3,243 participants. Data from the only hospital serving this population were included in the follow up. Throughout the study 132 participants were diagnosed with incident AS, defined as mean aortic valve gradient ≥15 mmHg. Cox proportional hazards regression disclosed age (HR 1.11, 95 %CI 1.08–1.14), systolic blood pressure (BP) (HR 1.01, 95 % CI 1.00–1.02), active smoking (HR 1.71, 95 % CI 1.09–2.67), and waist circumference (HR 1.02, 95 % CI 1.00–1.03) as independent predictors of incident AS. Analysis of risk factors for progression of AS disclosed a higher mean aortic gradient at first measurement (p = 0.015), weight (p = 0.015), a low haemoglobin (Hgb) (p = 0.030) and high density lipoprotein (HDL) (p = 0.032) as significant independent predictors. Age, systolic BP, smoking and waist circumference were independent predictors of incident AS, whereas cholesterol was not. Mean aortic gradient at first measurement, weight, an elevated HDL and low Hgb increase the progression rate of the disease. Our data indicate that calcific aortic valve disease is a distinct pathophysiological process, with age, smoking and “wear and tear” of the valve being major contributors to the disease development.
This is a preview of subscription content, log in to check access.
Tom Wilsgård for statistical support. This study was supported by the Northern Norway Regional Health Authorities (PhD Grant Number SFP-727-08).
Conflict of interest
Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation. 2005;111(24):3316–26.PubMedCrossRefGoogle Scholar
Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368(9540):1005–11.PubMedCrossRefGoogle Scholar
Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. cardiovascular health study. J Am Coll Cardiol. 1997;29(3):630–4.PubMedCrossRefGoogle Scholar
Lindroos M, Kupari M, Heikkila J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol. 1993;21(5):1220–5.PubMedCrossRefGoogle Scholar
Katz R, Wong ND, Kronmal R, et al. Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the multi-ethnic study of atherosclerosis. Circulation. 2006;113(17):2113–9.PubMedCrossRefGoogle Scholar
Stritzke J, Linsel-Nitschke P, Markus MR, et al. Association between degenerative aortic valve disease and long-term exposure to cardiovascular risk factors: results of the longitudinal population-based KORA/MONICA survey. Eur Heart J. 2009;30(16):2044–53. doi:10.1093/eurheartj/ehp287.PubMedCrossRefGoogle Scholar
Perkovic V, Hunt D, Griffin SV, du Plessis M, Becker GJ. Accelerated progression of calcific aortic stenosis in dialysis patients. Nephron Clin Prac. 2003;94(2):c40–5. doi:10.1159/000071280.CrossRefGoogle Scholar
Bahler RC, Desser DR, Finkelhor RS, Brener SJ, Youssefi M. Factors leading to progression of valvular aortic stenosis. Am J Cardiol. 1999;84(9):1044–8.PubMedCrossRefGoogle Scholar
Palta S, Pai AM, Gill KS, Pai RG. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation. 2000;101(21):2497–502.PubMedCrossRefGoogle Scholar
Nassimiha D, Aronow WS, Ahn C, Goldman ME. Association of coronary risk factors with progression of valvular aortic stenosis in older persons. Am J Cardiol. 2001;87(11):1313–4.PubMedCrossRefGoogle Scholar
Yamamoto K, Yamamoto H, Yoshida K, et al. Prognostic factors for progression of early- and late-stage calcific aortic valve disease in Japanese: the Japanese Aortic Stenosis Study (JASS) Retrospective Analysis. Hypertens Res. 2010;33(3):269–74. doi:10.1038/hr.2009.225.PubMedCrossRefGoogle Scholar
Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359(13):1343–56.PubMedCrossRefGoogle Scholar
Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O’Brien KD. Characterization of the early lesion of ‘degenerative’ valvular aortic stenosis. Histological and immunohistochemical studies. Circulation. 1994;90(2):844–53.PubMedCrossRefGoogle Scholar
Hermans H, Herijgers P, Holvoet P, et al. Statins for calcific aortic valve stenosis: into oblivion after SALTIRE and SEAS? An extensive review from bench to bedside. Curre Probl Cardiol. 2010;35(6):284–306. doi:10.1016/j.cpcardiol.2010.02.002.CrossRefGoogle Scholar
Otto CM, Burwash IG, Legget ME, et al. Prospective study of asymptomatic valvular aortic stenosis. clinical, echocardiographic, and exercise predictors of outcome. Circulation. 1997;95(9):2262–70.PubMedCrossRefGoogle Scholar
Ortlepp JR, Hoffmann R, Ohme F, Lauscher J, Bleckmann F, Hanrath P. The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis. Heart. 2001;85(6):635–8.PubMedCentralPubMedCrossRefGoogle Scholar
Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation. 2005;111(7):920–5. doi:10.1161/01.cir.0000155623.48408.c5.PubMedCrossRefGoogle Scholar